RANBAXY

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated May 09, 2012, titled "Ranbaxy sales grew over 55% with improvement in base business profitability".

Ranbaxy Laboratories Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 31-MAR-2012 as follows: Net Sales of Rs. 369540.3 lacs for quarter ending on 31-MAR-2012 against Rs. 214302 lacs for the quarter ending on 31-MAR-2011. Net Profit / (Loss) of Rs. 124676.4 lacs for the quarter ending on 31-MAR-2012 against Rs. 30438.7 lacs for the quarter ending on 31-MAR-2011.

Ranbaxy Laboratories Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2012 as follows: Net Sales of Rs. 181022.8 lacs for quarter ending on 31-MAR-2012 against Rs. 105644.4 lacs for the quarter ending on 31-MAR-2011. Net Profit / (Loss) of Rs. 82723.1 lacs for the quarter ending on 31-MAR-2012 against Rs. (5290.7) lacs for the quarter ending on 31-MAR-2011.

Ranbaxy Laboratories Limited has submitted to the Exchange the Standalone and Consolidated Financial Results along with Limited Review Report for the period ended March 31,2012.

Ranbaxy Laboratories Limited has informed the Exchange regarding the Proceedings of the Annual General Meeting of the Members of the Company held on May 08, 2012.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated April 25, 2012, titled "RANBAXY LAUNCHES SYNRIAM - INDIA'S FIRST NEW DRUG".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated April 19, 2012, titled "Daiichi Sankyo and Ranbaxy to expand Hybrid Business Model in Romania".

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on April 17, 2012, allotted 80,898 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 422,112,588 Equity Shares of Rs. 5 each aggregating Rs. 2,110,562,940/-.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated April 13, 2012, titled "Ranbaxy adjudged Malaysian Pharmaceutical Company of the Year for 2012".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated April 02, 2012, titled "Ranbaxy's Mohali SEZ Facility begins export of Atorvastatin to the US market".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated March 31, 2012, titled "RANBAXY RECEIVES APPROVAL TO MARKET RAN(TM) ROSUVASTATIN IN CANADA".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated March 12, 2012, titled "Ranbaxy opens New Manufacturing Facility in Morocco".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated March 06, 2012, titled "Ranbaxy Launches Atorvastatin in Germany - Agreement with Innovator allows early entry of generic before patent expiry - Synergistic Arrangement with Daiichi Sankyo Germany".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated March 06, 2012, titled "Ranbaxy Becomes The First Company To Launch Generic Atorvastatin in Italy, Netherlands & Sweden".

Ranbaxy Laboratories Limited has informed the Exchange that the auditors have conducted the limited review for the un-audited financial results for the quarter ended December 31,2011 A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RANBAXY_LR.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Limited has informed the Exchange that the Board of Directors at its meeting held on February 23, 2012 has decided to (1) convene the Annual General Meeting (AGM) of the Company on Tuesday, May 8, 2012. Share transfer books for the purpose of AGM will remain closed from April 28, 2012 to May 8, 2012 (both days inclusive).

Ranbaxy Laboratories Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on February 23, 2012 has decided to : (1) Re-appoint Mr. Arun Sawhney as CEO & Managing Director of the Company for a period of 5 years effective January 01, 2012, subject to requisite approvals.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated February 23, 2012, titled "Ranbaxy Crosses $2 BN In Global Sales".

Ranbaxy Laboratories Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended December 31,2011.

Ranbaxy Laboratories Limited has informed the Exchange regarding the standalone Results for the year ended on 31-DEC-2011 as follows: Net Sales of Rs. 747589.6 lacs for year ending on 31-DEC-2011 against Rs. 525148.6 lacs for the year ending on 31-DEC-2010. Net Profit / (Loss) of Rs. (305204.9) lacs for the year ending on 31-DEC-2011 against Rs. 114872.6 lacs for the year ending on 31-DEC-2010.

Ranbaxy Laboratories Limited has informed the Exchange regarding the consolidated Results for the year ended on 31-DEC-2011 as follows: Net Sales of Rs. 995784.5 lacs for year ending on 31-DEC-2011 against Rs. 853545 lacs for the year ending on 31-DEC-2010. Net Profit / (Loss) of Rs. (289972.9) lacs for the year ending on 31-DEC-2011 against Rs. 149675.1 lacs for the year ending on 31-DEC-2010.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated February 21, 2012, titled "Ranbaxy Launches Atorvastatin in Australia; First Company to introduce Generic Version".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated January 26, 2012, titled "Ranbaxy Announces court Filing of Consent Decree With U.S.Food and Drug Administration".

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on January 13, 2012, allotted 31,966 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 422,031,690 Equity Shares of Rs. 5 each aggregating Rs. 2,110,158,450/-.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated December 21, 2011, titled "Ranbaxy to Market Daiichi Sankyo's Innovative Products in Malaysia, Strategic Alliance Harnesses Synergies in ASEAN".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated December 21, 2011, titled "Ranbaxy Announces Consent Decree with U.S.Food And Drug Administration, takes Corrective Steps, commits to further measures."

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated December 06, 2011, titled "Ranbaxy Launches Authorized Generic Version of Caudet in the U.S.".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated December 01, 2011, titled "Ranbaxy Announces Launch of a Atorvastatin, Generic Lipitor(R), in the U.S.".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated November 11, 2011, titled "Ranbaxy and Daiichi Sankyo step up Community Initiatives".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated November 09, 2011, titled "Ranbaxy delivers strong overall base business performance and improvement in EBITDA margins".

Ranbaxy Laboratories Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended September 30,2011.

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on October 12, 2011, allotted 167,798 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 421,999,724 Equity Shares of Rs. 5 each aggregating Rs. 2,109,998,620/-.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated October 12, 2011, titled "Ranbaxy Honored with NJBIA Award For Excellence in New Jersey Business Expansion".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated October 04, 2011, titled "Ranbaxy to Extend Daiichi Sankyo Product Reach to Pharmacists Across Italy".

Ranbaxy Laboratories Limited has informed the Exchange that the Allotment Committee of Directors vide Resolution by Circulation passed on October 04, 2011, allotted 325,000 Equity Shares of Rs.5 each for cash at par to Ranbaxy ESOP Trust (Trust), set up to administer Ranbaxy Employee Stock Option Plan-2011. The Trust would allocate the shares to the employees of the Company and of its subsidiaries on exercise of stock options from time to time under Ranbaxy Employee Stock Option Plan-2011. The paid-up Equity Share Capital of the Company post allotment is 421,831,926 Equity Shares of Rs.5 each

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated September 05, 2011, titled "Ranbaxy UK Ltd. Launches esomeprazole - First approved generic version of the product to be made available in the UK".

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated August 31, 2011, titled "Daiichi Sankyo & Ranbaxy Announce a New Social Contribution Initiative Encompassing India, Cameroon and Tanzania".

Ranbaxy Laboratories Limited has submitted to the Exchange a copy of the disclosure under Regulation 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992

Ranbaxy Laboratories Limited has informed the Exchange that Mr. Indrajit Banerjee has joined as President & Chief Financial Officer of the Company on August 24, 2011. Mr. Banerjee is a Chartered Accountant and brings with him around 32 years of rich experience with the Organisations like PricewaterhouseCoopers (PWC), Indian Aluminium Company Limited, Lucent Technology, Lupin India Limited and Cairn India Limited.

Ranbaxy Laboratories Limited has informed the Exchange that the auditors have conducted the limited review for the un-audited financial results for the quarter ended June 30,2011. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RANBAXY_LR_18082011.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated August 12, 2011, titled "Ranbaxy introduces 'Volini Duo', a unique 2-in-1 Pain Killer, for the first time in India".

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated August 05, 2011, titled "Ranbaxy's base business across geographies continues to deliver strong results".

Ranbaxy Laboratories Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2011 as follows: Net Sales of Rs. 124178.3 lacs for quarter ending on 30-JUN-2011 against Rs. 106958 lacs for the quarter ending on 30-JUN-2010. Net Profit / (Loss) of Rs. 15037.5 lacs for the quarter ending on 30-JUN-2011 against Rs. (7.7) lacs for the quarter ending on 30-JUN-2010.

Ranbaxy Laboratories Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-JUN-2011 as follows: Net Sales of Rs. 205449.2 lacs for quarter ending on 30-JUN-2011 against Rs. 209878.1 lacs for the quarter ending on 30-JUN-2010. Net Profit / (Loss) of Rs. 24323.5 lacs for the quarter ending on 30-JUN-2011 against Rs. 32571.4 lacs for the quarter ending on 30-JUN-2010.

Ranbaxy Laboratories Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended June 30,2011.

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated August 02, 2011, titled "Daiichi Sankyo and Ranbaxy to Expand Hybrid Business Model in Mexico".

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated July 25, 2011, titled "Ranbaxy launches Letrozole Tablets on Day-1 in UK, Romania, France".

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on July 12, 2011 allotted 143,696 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 421,506,926 Equity Shares of Rs. 5 each aggregating Rs. 2,107,534,630/-.

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated July 12, 2011, titled "Ranbaxy enters into a licensing agreement with Gilead Sciences to manufacture and market three anti-HIV drugs in India and developing countries".

Ranbaxy Laboratories Limited has informed the Exchange that the auditors have conducted the limited review for the un-audited financial results for the quarter ended March 31,2011. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RANBAXY_LR_17052011.zip target=NEW> For more details click here.</a>